Skip to content
Open access

AI-driven discovery: A novel RANKL-targeting peptide for osteoporosis therapy

2026 · The Innovation Drug Discovery · 0 citations · 36 references

Abstract

The homeostasis between bone formation and resorption is essential for bone maintenance. Overactivation of bone resorption can lead to a decrease in bone density, an increase in bone fragility, and the development of osteoporosis. The Receptor Activator of Nuclear Factor κ B Ligand (RANKL) is a critical driver of bone resorption and a key therapeutic target for diseases like osteoporosis. Peptides, with their advantages of low immunogenicity and ease of synthesis, have emerged as promising drug candidates. Through a computational screening of approximately 100,000 peptide sequences using an AI-assisted strategy integrated with ADMET evaluation, we identified a novel class of RANKL-binding candidate peptides. Subsequent in vitro evaluation pinpointed R-Peptide as the lead candidate. In vivo validation further confirmed its anti-osteoclast effects in ovariectomized (OVX) mice and pro-osteogenic effects in wild-type (WT) mice. Mechanistically, R-Peptide significantly inhibited osteoclastogenesis by downregulating key marker genes (Ctsk, Trap, and Nfatc1) as well as critical components of the RANKL signaling pathway (RANKL and TRAF6). Taken together, this study identified a novel peptide that inhibits osteoclast differentiation and rescues bone loss in OVX mice, providing it as a promising therapeutic candidate for osteoporosis.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.